References
Shapiro S. Treating Thrombosis in the 21st Cen- tury. Editorial. N Eng J Med 2003;349: 1762-1764.
Albers G, Amarenco P, Donald Easton J, Sacco R, Teal P. Snthitrombotic and Thrombolytic Therapy for Ischemic Stroke. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:483S-512S.
Anthithrombotic Trialists`Collaboration. Col- laborative Meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ
;324:71-86.
Internacional stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or nei- ther among 19435 patients with acute ischemic stroke. Lancet 1997; 349:1569-1581.
CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: a randomised placebo controlled trial of early aspirin use in 20,000 patients with acute isch- emic stroke. Lancet 1997; 349:1641-1649.
Bayona H, Osuna E, Duarte M. Prevención de la Enfermedad Cerebrovascular y uso de la tera- pia antitrombótica. Revista Colombiana de Cardiología 2006;12(supl 1): 381-388.
CAPRIE Steering committee. A randomised, blinded trial of Clopidogrel Versus aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996; 348:1329-1339.
Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study-2. Dypiridamol and acetyl- salicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1-13.
Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. The Prevention Regimen for Eff ectively Avoiding Second Strokes (PRoFESS) trial. N Engl J Med 2008; 359: 1238–51.
Hankey G, Eikelboom J. Antithrombotic drugs for patients with ischaemic stroke and transient isch- aemic attack to prevent recurrent major vascular events. Lancet Neurol 2010;9:273-84.
Diener HC, Bogousslavsky J, Brass LM, Cimmi- niello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ, MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double- blind, placebo-controlled trial. Lancet 2004; 364:331-337.
Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–17.
Platelet-Oriented Inhibition in New Tran- sient Ischemic Attack (TIA) (POINT) trial. NCT00991029. http://www.clinicaltrials.gov/ct2/ show/NCT00991029 (accessed Dec 14, 2009).
Nisio M, Middeldorp S, Büller H. Direct Throm- bin Inhibitors. N Eng J Med 2005;353:1028-1040.
Albers GW, Diener HC, Frison L, et al. Ximela- gatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-8.
Connolly SJ, Ezekowitz MD,Yusuf S, et al. Dabiga- tran versus warfarin in patients with atrial fi brillation. N Engl J Med 2009;361: 1139–51.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.